Salud mental · Medicamentos
How to prepare for an ADHD medication visit
What to bring and what to ask before an ADHD medication visit, plus how common medicines differ in coverage, side effects, and safety.
Publicado:
Information updated: October 12, 2026
Before your visit
Bring a few facts so the appointment can be about choices, not reconstruction.
- Your current medicines, with the dose and the time of day you take them
- When symptoms get in the way: school, work, evening, driving, or home
- ADHD medicines you have already tried, and what happened
- Sleep, appetite, and other health conditions or medicines
- Two or three daily-life goals, such as finishing a morning routine
Questions to bring to your appointment
- What are the specific goals of my treatment?
- Why does this medication fit my health history and schedule?
- When should benefit begin, and how long is a fair trial?
- What side effects should I report, and which require urgent care?
- What should I do if I miss a dose or cannot get a refill?
- Does this exact formulation have special food or swallowing instructions?
- What will we monitor, and when is my next follow-up?
- What other support would help me use the benefits of treatment?
Finding an ADHD treatment can take patience. One person may do well with a short-acting tablet. Another may need coverage through an evening shift, a medication that is easier to swallow, or a nonstimulant. The goal is meaningful improvement in daily life with side effects you can manage.
This guide explains the major medication families and common U.S. formulations. It can help you prepare for a conversation with your clinician. It is not a prescription or a guide to changing your dose yourself. Brand availability, insurance coverage, and approved age ranges vary by product.
Start here: Five things to know
- There is no single best ADHD medication for everyone. Your response and priorities matter.
- ADD and ADHD do not require separate medication lists. “ADD” usually refers to ADHD with predominantly inattentive symptoms.
- The release system matters. Two products with the same active ingredient can start working and wear off at different times.
- Longer coverage is useful only when you need it. Medication that lasts into the evening can help some people and interfere with sleep for others.
- Treatment includes more than medication. Skills, routines, therapy, family support, and school or workplace accommodations can all have a role (Centers for Disease Control and Prevention [CDC], n.d.; National Institute of Mental Health [NIMH], n.d.).
What is ADHD, and where does “ADD” fit?
Attention-deficit/hyperactivity disorder, or ADHD, is a developmental condition that can affect attention, organization, activity level, and impulse control. It can continue into adulthood. Some people mainly have inattentive symptoms, some mainly have hyperactive or impulsive symptoms, and others have both.
You do not have to appear visibly hyperactive to have ADHD. The older term “ADD” is commonly used for the predominantly inattentive presentation. Medication selection depends on your symptoms, health history, needs, and response—not simply which presentation you have (NIMH, n.d.).
What should medication help with?
Medication may make it easier to sustain attention, follow through, pause before acting, or manage restlessness. Progress should show up in everyday life. Examples might include completing a household task, following a conversation, keeping appointments, or getting through a school day with fewer disruptions.
Agree on a few specific goals with your clinician. “I want to finish my morning routine without missing three steps” is easier to evaluate than “I want to feel more productive.” Medication does not replace organizational skills, and increased wakefulness alone does not show that ADHD is well treated (NIMH, n.d.).
How medications differ
Stimulants
The established stimulant families are methylphenidate and amphetamines. They affect dopamine and norepinephrine, chemical messengers involved in attention and behavior. A benefit may be noticeable on a day the medication is taken, although finding a suitable dose and formulation takes longer.
Common adverse effects include reduced appetite, trouble sleeping, headache, stomach discomfort, irritability, and increased heart rate or blood pressure. Established methylphenidate and amphetamine ADHD products are Schedule II controlled substances. They carry warnings about misuse, addiction, overdose, and sharing medication (U.S. Food and Drug Administration [FDA], 2023).
Nonstimulants
Atomoxetine, viloxazine ER, guanfacine ER, and clonidine ER are established nonstimulant options. They are not controlled substances. They generally require consistent daily treatment and gradual assessment rather than a one-dose trial. Each has its own risks; “nonstimulant” does not mean “no side effects” (National Library of Medicine [NLM], n.d.).
Off-label medications
Sometimes a clinician recommends a medicine that is FDA-approved for another condition but not specifically for ADHD. This is called off-label use. It requires a discussion of the evidence, alternatives, risks, and reason for choosing it. Bupropion is one example.
Reading medication names and duration estimates
| Term | What it means |
|---|---|
| Immediate release, or IR | Releases medication relatively quickly; often requires more than one daily dose. |
| Extended release, or ER/XR/LA | Releases medication over time. These abbreviations do not identify one standard release pattern. |
| Delayed release | Waits before releasing medication. Jornay PM uses delayed and extended release. |
| ODT | A tablet that dissolves in the mouth. It is not necessarily short-acting. |
| Prodrug | A substance the body converts into an active medication. |
| Rebound | A temporary increase in symptoms or irritability as medication wears off. |
The time ranges below are estimates, not promises. They combine typical clinical coverage with findings from product studies. Studies used different populations and measurements, so the numbers cannot be used to rank effectiveness. Your useful coverage may be shorter. A drug’s half-life—the time it takes the body to reduce its level by half—is not the same as its symptom-control window.
Do not compare doses by the milligram number alone. Different ingredients, salt forms, and release systems can require different dosing. Do not substitute, split, crush, open, or dissolve a product unless its instructions specifically allow it (NLM, n.d.).
Methylphenidate medications
Methylphenidate products differ mainly in release pattern and delivery form. Dexmethylphenidate is a closely related active form. This table lists common and established formulations; it is not a guarantee that every brand is currently stocked.
| Medication | Approximate useful coverage | Why it may be considered | What to discuss |
|---|---|---|---|
| Methylphenidate IR: Ritalin, Methylin, generics | About 3–4 hours per dose | Flexible timing; tablets, liquid, or chewable options | Repeat dosing and symptoms between doses |
| Older methylphenidate SR/ER tablets | Often about 6–8 hours | Intermediate coverage | The exact release formulation; ER products are not all equivalent |
| Ritalin LA and corresponding formulations | Often about 6–8 hours | Two release phases; some capsules permit sprinkling | Afternoon or evening coverage |
| Metadate CD and corresponding formulations | Often about 6–8 hours | A different balance of early and later release | Meal instructions and when symptoms return |
| Concerta and corresponding generics | About 10–12 hours | Once-daily osmotic delivery | Must swallow whole; confirm the exact dispensed product |
| Relexxii | About 12 hours | Osmotic delivery with additional intermediate strengths | Must swallow whole; it contains methylphenidate, not a different active medicine |
| Aptensio XR | Up to about 12 hours | Extended-release capsule; sprinkle option | Individual onset, duration, and food instructions |
| Quillivant XR | Up to 12 hours | Extended-release liquid | Shake as directed and measure with the supplied device |
| QuilliChew ER | Benefit through about 8 hours in pivotal testing | Extended-release chewable | Whether coverage lasts long enough for your day |
| Cotempla XR-ODT | Up to 12 hours | Dissolving tablet | Pediatric labeling and product-specific strengths |
| Jornay PM | Next-morning and daytime coverage | Evening dosing intended to address symptoms upon awakening | Timing is different from morning stimulants; insomnia can occur |
| Daytrana | Depends on patch wear time; effects continue after removal | Nonoral delivery; some control over exposure by removal time | Skin irritation, potential persistent loss of skin color, and heat exposure |
| Dexmethylphenidate IR: Focalin, generics | About 4–5 hours | Short-acting active form of methylphenidate | Smaller milligram doses do not mean weaker treatment |
| Dexmethylphenidate XR: Focalin XR, generics | About 8–12 hours | Two-phase delivery; sprinkle option | Actual duration and late-day symptoms |
| Serdexmethylphenidate/dexmethylphenidate: Azstarys | Up to 13 hours | Combines active medication with a prodrug | Different dosing from Focalin or methylphenidate |
Sources: Individual prescribing information in DailyMed, including Ritalin LA, Metadate CD, Relexxii, Quillivant XR, QuilliChew ER, Cotempla XR-ODT, Jornay PM, Daytrana, Focalin XR, and Azstarys (NLM, n.d.).
A useful distinction: If a medicine helps during its active hours but ends too early, a different release system may help. If side effects occur throughout the day, simply extending the same drug may not solve the problem.
Amphetamine medications
Amphetamine products differ in their ingredient mixture and how medication reaches the bloodstream. Some contain mixed amphetamine salts, some contain dextroamphetamine, and others use a prodrug or another delivery system.
| Medication | Approximate useful coverage | Why it may be considered | What to discuss |
|---|---|---|---|
| Mixed amphetamine salts IR: Adderall, generics | About 4–6 hours per dose | Flexible timing | Repeat doses, rebound, and sleep |
| Mixed amphetamine salts XR: Adderall XR, generics | About 10–12 hours | Once-daily, two-phase release | Whether useful coverage reaches the evening |
| Mixed amphetamine salts triple-release: Mydayis | Up to 16 hours | Longer coverage into the evening | Approved for age 13+; prolonged appetite or sleep effects |
| Lisdexamfetamine: Vyvanse, generics | Often about 10–13 hours; adult studies show benefit through 14 hours | Prodrug converted to dextroamphetamine; capsule and chewable forms | Onset can be slower than IR products; it remains a controlled stimulant |
| Dextroamphetamine IR: Zenzedi, ProCentra, generics | About 4–6 hours | Tablet or liquid; dextroamphetamine alone | Individual tolerability; it is not universally smoother than mixed salts |
| Dextroamphetamine ER: Dexedrine Spansule, generics | Often about 6–8 hours | Sustained delivery of dextroamphetamine | May not cover a long workday |
| Amphetamine sulfate: Evekeo and related formulations | Often about 4–6 hours | Different amphetamine mixture from Adderall | Exact formulation, approved age range, and dose |
| Amphetamine ER-ODT: Adzenys XR-ODT | About 10–12 hours | Dissolving tablet | Product-specific conversion; do not match milligrams to Adderall |
| Amphetamine ER: Dyanavel XR | Up to about 13 hours | Liquid or tablet | Product-specific dosing and administration |
| Dextroamphetamine patch: Xelstrym | Depends on application and wear time | Nonoral option | Apply 2 hours before needed; remove within 9 hours; avoid external heat |
| Methamphetamine: Desoxyn/generic | Short-acting; individualized | An older approved option used infrequently | Misuse risk and reasons to prefer more established routine options |
Sources: Individual prescribing information in DailyMed, including Adderall XR, Mydayis, Vyvanse, Evekeo, Adzenys XR-ODT, Dyanavel XR, Xelstrym, and Desoxyn (NLM, n.d.).
For patches, removal does not instantly end medication effects. Follow instructions for application, removal, disposal, and avoiding heat. Do not cut a patch to change the dose.
Mydayis, Adderall XR, and Vyvanse: What is the difference?
Mydayis contains the same mixture of amphetamine salts as Adderall XR, but uses three release phases instead of two. Vyvanse uses a different approach: the body converts its prodrug into dextroamphetamine.
| Mydayis | Adderall XR | Vyvanse | |
|---|---|---|---|
| Delivery approach | Three release phases | Two release phases | Prodrug conversion |
| Approximate upper coverage window | Up to 16 hours | About 12 hours | Up to 13–14 hours in studied settings |
| Minimum labeled ADHD age | 13 years | 6 years | 6 years |
| Possible practical advantage | Evening coverage | Conventional once-daily amphetamine option | A different delivery approach that some people prefer |
| Possible drawback | Effects may last beyond the useful day | May wear off too early | May start too slowly or still end too early |
Mydayis can be worth discussing when an amphetamine already helps but does not last long enough. It is not automatically stronger or better. Its label directs morning dosing upon awakening; a missed dose should not be taken later in the day. It cannot be substituted milligram-for-milligram for another amphetamine (NLM, n.d.).
Nonstimulant options
Atomoxetine: Strattera and generics
Atomoxetine affects norepinephrine and is approved for children age 6+ and adults. It can be useful when stimulants are unsuitable or a noncontrolled medicine is preferred. A fair assessment usually takes several weeks; it is not an as-needed medicine.
Possible effects include nausea, fatigue, reduced appetite, sexual problems, and difficulty urinating. Blood pressure and heart rate can rise. Its boxed warning addresses suicidal thoughts in children and adolescents. Rare severe liver injury is another warning; contact your clinician promptly for yellow skin or eyes, dark urine, or unexplained upper abdominal pain (NLM, n.d.).
Viloxazine ER: Qelbree
Qelbree is a once-daily noncontrolled option for children age 6+ and adults. Its capsule may be opened only as directed in the product instructions.
It can cause sleepiness, fatigue, nausea, reduced appetite, or insomnia. It carries a boxed warning for suicidal thoughts and behaviors and can increase blood pressure or heart rate. It also interacts with several medicines through liver enzymes, especially CYP1A2. A pharmacist or prescriber should review the entire medication list (NLM, n.d.).
Guanfacine ER: Intuniv and generics
Guanfacine ER may be used alone or with a stimulant. U.S. ADHD approval and supporting pediatric studies concern ages 6–17; adult use is off-label. It may be considered when hyperactivity or impulsivity remains troublesome or when a stimulant is not suitable.
Sleepiness, dizziness, low blood pressure, and a slow pulse can occur. Do not stop it suddenly: your clinician should provide a taper to reduce the risk of rebound high blood pressure (NLM, n.d.).
Clonidine ER: Tablets and Onyda XR liquid
Clonidine ER is another pediatric option used alone or with a stimulant. Extended-release tablets, historically known as Kapvay, are often taken in divided doses. Onyda XR is an extended-release liquid taken once nightly and is approved for pediatric patients age 6+.
Clonidine can cause substantial sleepiness, low blood pressure, and a slow pulse. It requires a supervised taper. Different clonidine products should not be exchanged by matching the milligram dose (NLM, n.d.).
A newly approved treatment: Simtriyo
Status checked October 12, 2026. Simtriyo, or centanafadine ER, was FDA-approved on July 24, 2026, for adults and children age 6+ weighing at least 20 kg (44 pounds). It affects norepinephrine, dopamine, and serotonin reuptake. The approved label calls it a central nervous system stimulant.
The manufacturer currently reports that it is not yet commercially available while DEA scheduling is under review. Approval does not establish superiority over existing medicines. Its warnings include suicidal thoughts and behaviors, misuse and addiction, cardiovascular and psychiatric effects, and serotonin syndrome. Availability and prescribing information should be rechecked when considering treatment (FDA, 2026; Otsuka, n.d.).
Other medicines sometimes used off-label
| Medicine | Possible role | Important limitation |
|---|---|---|
| Bupropion, including Wellbutrin SR/XL | Selected adults with ADHD and depression; some formulations are also used for smoking cessation | Less established for ADHD than first-line options; seizure risk; contraindicated with seizure disorders or current/past anorexia nervosa or bulimia |
| Guanfacine IR or clonidine IR | Selected ADHD or tic-related treatment plans | Different from ER products; sedation, low blood pressure, and withdrawal-related BP changes |
| Tricyclic antidepressants such as desipramine, nortriptyline, or imipramine | Selected specialist-managed cases | Heart-rhythm/conduction risks, other adverse effects, and overdose toxicity |
| Modafinil or armodafinil | Occasionally considered by specialists | Not approved for ADHD; evidence limitations and serious rash concerns |
| Other antidepressants | Occasionally considered when another condition is central to care | Most are not established treatments for core ADHD symptoms |
An antidepressant that improves concentration by treating depression is not necessarily treating ADHD itself. Your clinician should explain the intended target (NIMH, n.d.; NLM, n.d.).
How do we choose a treatment?
Bring your daily schedule into the conversation. The most useful medicine for a student who needs school-day coverage may differ from one for an adult working evenings.
Discuss when symptoms cause difficulty, prior medication experiences, sleep, appetite, health conditions, other medicines, and your preferences about controlled substances and dosage forms. Cost and a reliable supply also matter.
Methylphenidate is a common initial medication choice for children. Methylphenidate or lisdexamfetamine are common adult options. A poor response to one does not prove that every stimulant will fail. When an adequate trial is ineffective or poorly tolerated, a clinician may change the formulation, try another medication family, or choose a nonstimulant (National Institute for Health and Care Excellence [NICE], 2018).
Children, adolescents, and adults have different needs
Children younger than 6: Parent training in behavior management is generally recommended first. Medication decisions require a separate preschool assessment. Some older labels include younger ages, but this does not make those products preferred treatment. FDA warns that children under 6 can have higher exposure and more adverse effects with ER stimulants.
School-age children and adolescents: Medication can be combined with behavioral treatment and school supports. Growth, appetite, sleep, learning, and the young person’s own experience should be followed. Help adolescents build safe medication habits without framing treatment as punishment.
Adults: Treatment goals may involve work, driving, relationships, household tasks, or education. Review other health conditions and medicines as well as symptom scores. Not every pediatric formulation has an adult indication (CDC, n.d.; FDA, 2025; NIMH, n.d.).
Starting treatment and tracking progress
Before treatment, your clinician should review medical and mental-health history, current medicines, blood pressure, pulse, weight, and relevant cardiac or family history. Children also need growth monitoring. An ECG is not automatically necessary for everyone; symptoms, examination, and history guide additional testing (NICE, 2018).
Ask when your first follow-up will occur and how to reach the team if problems arise. Early appointments are often closer together during dose adjustment. Agree on the plan before leaving the visit.
For a brief daily record, note:
- The medication and time taken.
- One or two agreed daily-life goals.
- When benefit begins and when symptoms return.
- Appetite, meals, and sleep.
- Side effects and any missed doses.
Bring the record to follow-up. A pattern is more useful than trying to remember how an entire month felt.
Common problems and what to do
| Problem | A useful next step |
|---|---|
| Reduced appetite or weight loss | Tell your clinician. Ask about meal timing, nutrition, dose, or a different formulation. Children need growth follow-up. |
| Trouble sleeping | Record dose time, caffeine use, and sleep timing. Discuss duration and timing before adding a sleep medicine. |
| Irritability as medication wears off | Record when it occurs; the clinician can distinguish rebound from an adverse effect or another condition. |
| Feeling emotionally flat, unusually anxious, or unlike yourself | Contact the prescriber rather than accepting this as the price of treatment. |
| Dizziness or faintness on guanfacine or clonidine | Sit or lie down safely and contact your clinician; these medicines can lower BP and pulse. Fainting needs prompt assessment. |
| No clear improvement | Review adherence, the trial length, dose, treatment goals, and diagnosis before deciding the medicine has failed. |
| Helpful at school or work but ineffective at home | Bring the timing pattern to follow-up; coverage may need reassessment. |
Do not increase your dose or add leftover medication yourself. These suggestions support a conversation; they do not replace product-specific instructions (NLM, n.d.).
When to get help urgently
Call 911 for chest pain with concerning symptoms, severe trouble breathing, collapse, seizure, stroke-like symptoms, or a severe allergic reaction. Seek emergency assessment for severe confusion, agitation, high fever, or muscle rigidity, especially after a medication change or combination.
New hallucinations, extreme agitation, or possible mania need urgent clinical assessment. For suicidal thoughts, call or text 988 in the United States; call 911 if there is immediate danger. Suicidal thoughts in a child taking ADHD medication also require prompt contact with the treating clinician.
For a suspected overdose, accidental ingestion, or medication error, contact Poison Control at 1-800-222-1222 immediately. Call 911 first if the person has collapsed, is having a seizure, or cannot breathe normally. Do not wait for a routine portal reply (FDA, 2023; NLM, n.d.).
Taking medication safely
Follow your own prescription and medication guide. Never share medicine or take another person’s prescription. Store controlled medication securely and use an authorized take-back option for unused supplies.
Missed-dose instructions vary. Do not double a dose unless specifically directed. Mydayis should not be taken late after a missed morning dose. With guanfacine or clonidine, several missed doses may require guidance before restarting, and stopping abruptly can cause rebound hypertension.
Ask before crushing tablets, opening capsules, mixing medicine into food, or changing a patch’s wear time. Use an oral dosing device for liquids, not a kitchen spoon (FDA, 2023; NLM, n.d.).
Other conditions, pregnancy, and interactions
Tell your clinician about heart disease, fainting, high blood pressure, tics, bipolar disorder, psychosis, seizures, eating disorders, liver or kidney disease, and substance use. These details help determine what is appropriate; they do not automatically rule out every ADHD treatment.
Bring a complete list of prescriptions, over-the-counter medicines, supplements, caffeine or energy products, nicotine, alcohol, and cannabis. Some antidepressants, decongestants, and other medicines can change ADHD medication effects. MAO inhibitors have serious interactions with several ADHD drugs. Qelbree and atomoxetine also have important enzyme-related interactions.
If you are pregnant, planning pregnancy, or breastfeeding, request an individualized review. The discussion should consider medication exposure and the effects of untreated ADHD. Do not assume that a nonstimulant is safer or abruptly change treatment on your own (NLM, n.d.).
Treatment beyond medication
Medication can make skills easier to use, but skills and support remain valuable. Options may include cognitive behavioral therapy, organizational strategies, parent training, classroom supports, predictable routines, reminders, and school or workplace accommodations. Regular sleep, meals, and movement support general well-being.
You do not need to build a perfect system before seeking care. Start with one problem that matters to you and one change you can realistically maintain (CDC, n.d.; NIMH, n.d.).
Cost, coverage, and pharmacy access
Ask about the exact drug, formulation, strength, and available generic. “Methylphenidate ER” or “amphetamine ER” alone may not identify the intended product. Insurance may cover one formulation and require authorization for another.
If a pharmacy cannot fill the prescription, contact your care team before rationing, borrowing, or substituting medication. A different strength or product may need a new prescription and a different dosing plan. Tell the team if cost, transportation, language, or difficulty managing refills is making treatment harder.
Frequently asked questions
Will medication change my personality?
The goal is better functioning with tolerable effects. Feeling emotionally flat, unusually irritable, or unlike yourself deserves a review of the dose and treatment choice.
Is Mydayis better than Adderall XR?
Neither is universally better. Mydayis usually offers a longer coverage window, which can be helpful for evening needs and problematic for sleep.
Does a higher milligram dose mean a stronger medicine?
Not across different products. The printed strengths are not a universal scale of effect.
Can I take medication only on work or school days?
Only with an agreed plan. Some nonstimulants require consistent daily treatment, and guanfacine or clonidine should not be stopped suddenly. ADHD can affect home life and driving as well as school or work.
Can a stimulant and a nonstimulant be combined?
Sometimes. Certain ER guanfacine and clonidine products are approved as adjuncts to stimulants in pediatric treatment. Combinations require monitoring and are not automatically better.
Does a stimulant response prove I have ADHD?
No. Diagnosis requires a clinical assessment. A medication response alone does not establish it.
Does ADHD medication cause addiction?
Stimulants have misuse and addiction risks. Taking medicine as prescribed, secure storage, and follow-up help manage those risks. Physical dependence and addiction are different concepts; discuss concerns openly rather than stopping treatment without guidance.
How long will I need treatment?
There is no universal timeline. Reassess benefits, adverse effects, and changing needs with your clinician. Any trial off medication should be planned, with tapering when needed.
Talk with RootBound Health
Bring your questions, your medication list, and what daily life has actually been like. A useful treatment conversation includes what helps, what feels wrong, and what is getting in the way—including cost, sleep, side effects, and the effort of managing the plan.
An evaluation does not guarantee a particular diagnosis or prescription. Treatment depends on your clinical needs, safety, and available services.
Selected prescribing information
Fuentes
- Treatment of ADHD — CDC
- Attention deficit hyperactivity disorder: Diagnosis and management (NG87) — NICE
- ADHD in adults: 4 things to know — NIMH
- DailyMed — National Library of Medicine
- Simtriyo: Now FDA approved — Otsuka
- FDA updating warnings to improve safe use of prescription stimulants — FDA
- FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD — FDA
- Simtriyo (centanafadine) extended-release capsules prescribing information — FDA